BioCryst launches Orladeyo (berotralstat) in Portugal

BioCryst Pharmaceuticals announced that Infarmed in Portugal has recommended Orladeyo (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.

“The positive Infarmed recommendation of Orladeyo broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Portugal,” said Charlie Gayer, chief commercial officer of BioCryst.

The Infarmed decision in Portugal follows the European Commission marketing authorization of Orladeyo in April 2021. To date, Orladeyo is licensed in 44 countries.

(Source: BioCryst)